Galera Therapeutics, Inc. 8-K

What Happened
Galera Therapeutics, Inc. (GRTX) filed an Item 8.01 8-K on April 3, 2026 announcing its 2026 Annual Meeting of Stockholders is scheduled for May 8, 2026. Because that date is more than 60 days after the anniversary of the prior meeting (held Feb 24, 2025), the company set new advance-notice deadlines for stockholder nominations and proposals under its Amended and Restated Bylaws and applicable SEC rules. The filing was signed by President and CEO J. Mel Sorensen, M.D.

Key Details

• Annual Meeting date: May 8, 2026.
• Deadline for advance notice of director nominations or other shareholder business under the Bylaws: delivery to the company secretary (Joel Sussman) at Galera’s principal executive office no later than April 13, 2026. Address: 101 Lindenwood Drive, Suite 225, Malvern, PA 19355.
• Universal proxy (Rule 14a-19): shareholders seeking to solicit proxies for nominees other than the company’s nominees must provide the information required by Rule 14a-19(b) and have that notice postmarked or transmitted to the company no later than April 13, 2026.
• Rule 14a-8 shareholder proposals for inclusion in the company’s proxy materials must be received a “reasonable time” before printing; the company will treat proposals received on or before April 13, 2026 as timely.

Why It Matters
If you plan to nominate a director or submit a proposal for Galera’s 2026 Annual Meeting, you must meet the April 13, 2026 deadlines and follow the company’s Bylaws plus SEC rules (14a-8 for inclusion in proxy materials and 14a-19 for universal proxy-related solicitations). Missing these deadlines generally means your nomination or proposal will not be considered at the meeting, limiting shareholder influence over board composition and agenda items.